A multicentric noninterventional trial (open study without control) to investigate the efficacy and tolerance of a drug in a large number of patients under routine medical conditions was performed for a new solid preparation from an extract of the fruit of Vitex agnus castus (VAC, Vitex, chaste tree, Chasteberry) in 1634 patients suffering from premenstrual syndrome (PMS). A specific questionnaire was developed for determining the effect of Vitex on psychic and somatic complaints, on the four characteristic PMS symptom complexes depression, anxiety, craving, and hyperhydration (DACH), and on single groups of symptoms. After a treatment period of three menstrual cycles 93% of patients reported a decrease in the number of symptoms or even cessation of PMS complaints. To a certain extent, this effect was observed within all symptom complexes and correlated with the global assessment of therapeutic efficacy. Whereas 85% of physicians rated it as good or very good, 81% of patients assessed their status after treatment as very much or much better. Analysis of frequency and severity of mastodynia as the predominant symptom revealed that complaints still present after 3 months of therapy were mostly less severe. Ninety-four percent of patients assessed the tolerance of Vitex treatment as good or very good. Adverse drug reactions were suspected by physicians in 1.2% of patients, but there were no serious adverse drug reactions. Hence, the risk/benefit ratio of the new Vitex preparation can be rated as very good, with significant efficacy for all aspects of the multifaceted and inhomogeneous clinical picture of PMS, with a safety profile comparable to other Vitex preparations. 315 
INTRODUCTION T
HE M EN STRUA L CYCLE REAC TS sensitively to many influences on the regulative system of the central nervous structures (hypothalamus and pituitary gland) and the ovaries as peripheral target organs. Pathological changes in this sensitive system can cause a wide range of complaints and diseases, requiring an effective as well as a tolerable therapeutic strategy.
In this context, the premenstrual (tension) syndrome (PMS) is very important. PMS is characterized by psychic and somatic symptoms typically occurring in the second part of the female cycle and disappearing with the onset of or during menstrual bleeding. 1 Up to 150 different symptoms have been recorded as part of PMS. Because the multitude of heterogeneous symptoms can be attributed to the four subgroups, depression, anxiety, craving, and hyperhydration, 2, 3 PMS may also be referred to as the DACH syndrome (for single symptoms of these subgroups, see Table 1 ).
According to the scientific literature, the prevalence of PMS is about 30%-40% in fertile women, and 5%-10% suffer from severe complaints. 4 A recent investigation involving students of pharmacy at Basel University (n 5 132) revealed a prevalence of 70% regardless of the intake of oral contraceptives. 5 The etiology of PMS has not been completely explained, and several mechanisms are being discussed 5 : estrogen and gestagen imbalance, deficiency of prostaglandins, essential fatty acids, vitamin B 6 , serotonin, or other neurotransmitters, and hyperprolactinemia, especially where the predominant symptom is mastodynia. 4 Therefore, various therapeutic strategies have been employed, such as hormone therapies, substitution of essential fatty acids, and the use of pyridoxine and psychiatric drugs, but either benefits are controversial, 1, 5 or side effects limit the use of these therapies.
Thus, there is a need for a treatment that alleviates both somatic and psychic complaints and that has a good tolerance. In the last decades, phytopharmaceutic preparations containing Vitex agnus castus (VAC) extracts have been used. Vitex (chaste tree, chasteberry) is a bushy plant native to the Mediterranean countries and Asia. Extracts from its fruit (Agni casti fructus) have been used for treating gynecological complaints since Greek antiquity. 6 At present, scientifically developed and well-accepted pharmaceuticals contain such extracts as the active ingredient. The German monograph on Vitex documents three indications, PMS, mastodynia, and menstrual rhythm anomalies, that can be treated with Vitex.
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The mode of action of Vitex is not completely understood. 6 Presumably, different mechanisms contribute to the therapeutic effects, one of which is a decrease in prolactin via dopamine-D2 receptor binding at the pituitary gland. [8] [9] [10] Furthermore, binding affinities of a special Vitex extract to opioid receptors, the histamine H 1 receptor, and estrogen receptors were observed recently. 5 There is clinical evidence for the efficacy of various Vitex extracts. With respect to the symptom rhythm anomalies, the superiority of a Vitex extract versus placebo was demonstrated in a 3-month randomized trial. 11 Effects on the symptom, mastodynia, were shown in a randomized placebo-controlled trial. 10 Therapeutic effects for PMS were documented in drug-monitoring studies (reviewed in ref. 5 ). In a controlled study comparing 3 months of therapy with either vitamin LOCH ET AL. 316 Because the origin of the plant material and the extraction procedure are decisive factors in the efficacy and tolerance of the phytopharmaceutical, 6 we initiated this study to review these parameters for a new Vitex preparation under routine medical conditions. The major objective of such a noninterventional trial is to gather medical experience on the efficacy and tolerance of an established product in a systematic and scientifically reliable manner during routine medical work in a doctor's practice. The therapeutic effect of the Vitex preparation on any of the four classic PMS complexes (DACH syndrome) and any other typical symptoms was assessed. Mastodynia especially, as the most common PMS symptom, was analyzed for frequency and severity.
MATERIALS AND METHODS
In a multicenter noninterventional trial, data on 1634 patients were obtained by 857 gynecologists in Germany to assess information about the efficacy and safety of a new Vitex preparation (Femicur ® capsules, Schaper & Brümmer GmbH & Co. KG, Salzgitter, Germany) (one capsule containing 1.6-3.0 mg dried extract of Agni casti fructus [6.7-12.5:1], corresponding to 20 mg drug) used in daily practice. The investigators were informed about the characteristics of this phytopharmaceutical and its directed use, including the recommended dosage (one capsule twice daily). Suffering from PMS was the only inclusion criterion. Pregnant patients were excluded from treatment, but no further instructions concerning the therapy were given.
When Femicur ® was given as therapy of PMS, the investigator was asked to fill in one questionnaire at the start of therapy and another one after a period of three menstrual cycles under therapy. In accordance with the prospectively implemented study protocol, these questionnaires were used by all investigators. The questionnaires consisted of items questioning the efficacy and tolerance of the treatment. They were filled in by the investigator after interviewing the patient.
Efficacy
The investigator documented the occurrence of typical PMS symptoms in the beginning and at the end of therapy. The decrease in frequency at which symptoms were occurring was used as a measure of efficacy (Table 1) . Mastodynia, as the most prominent symptom of PMS, was documented qualitatively and quantitatively ( Table 2) .
The global efficacy was rated by the investigator on a four-category scale (very good efficacy to no efficacy) based on an interview after 3 months of treatment. Each patient assessed her global improvement according to the Clinical Global Impression Scale 13 (CGI 2), using a scale with seven categories (very much improved to very much worse). 
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Tolerance
Tolerance was assessed by the patient on a four category scale (very good to bad), and adverse events were recorded. Data were entered into a database and analyzed using the statistical software WinSTAT ® 3.1 (Kalmia Co. Inc., Cambridge, MA).
The conduct and analysis of this trial followed the recommendations on the conduct of noninterventional trials drawn up by the German Society for Medical Informatics, Biometry and Epidemiology (GMDS) at the instigation of the German Federal Institute for Drugs and Medical Devices (BfArM).
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RESULTS
Questionnaires were completed for 1698 patients, and 1634 were suitable for analysis. Thirtyone patients enrolled initially did not return for the second interview and gave no reason, 18 patients were excluded from the efficacy analysis because they did not suffer from PMS, 3 questionnaires showed a severe lack of relevant information, and in 12 cases, the questionnaires were returned after closure of the database. Among the valid cases, 119 patients (7%) had terminated the treatment prematurely ( Table 3) .
The 1634 patients in the valid-case population had a mean age of 35.8 6 8.7 years, a height of 167.0 6 5.5 cm, and a body mass index (BMI) of 23.1 6 3.2. They had suffered from PMS for 151 6 179 weeks with a mean of 4 6 2 different symptoms and 9 6 4 days with PMS complaints per menstrual cycle.
The efficacy and tolerance of Vitex treatment were evaluated after 99 6 22 days of treatment.
Efficacy
Forty-two percent of patients reported that they were no longer suffering from PMS, 51% showed a decrease in symptoms, and 1% experienced an increase in the number of symptoms. In 6% of patients, the frequency of symptoms did not change. Table 1 shows details of the frequency of the different groups of PMS symptoms and the DACH complexes before and after treatment. Patients still suffering from PMS reported complaints on 5 6 3 days (before therapy 9 6 4 days) with 2 6 1 different symptoms (before therapy 4 6 2) per menstrual cycle. The decrease under therapy was statistically significant for both parameters (p , 0.001, paired samples t-test, Wilcoxon test). Mastodynia was the most frequent symptom in this trial. With treatment, its frequency decreased, and the severity was reduced as well ( Table 2) .
The results of assessment of the efficacy of treatment are shown in Figure 1 . A clear improvement was assessed by 80% of the patients, and 86% of the physicians documented a pronounced efficacy.
Tolerance
In the patients' self-assessment, the tolerance was described as good or very good in 94% of cases (Fig. 2) . For the total population of 1698 patients, 45 adverse events or symptoms were documented in 37 patients (2%) and none were serious. In 20 patients (1%) with 23 adverse events, a correlation with the intake of Vitex was assumed by the investigators. Table 4 shows details about the nature of these suspected adverse drug reactions.
During the period of treatment with Vitex, 23 patients became pregnant, and in 12 patients the treatment was terminated because of the pregnancy.
Compliance
In accordance with the German monograph, 90% of the investigators had prescribed a daily dosage of extract corresponding to 40 mg of Agni casti fructus. Patient compliance, as monitored by the investigators, was 98%.
DISCUSSION
The efficacy of Vitex in menstrual disorders and its good tolerance have been demonstrated in several trials. 6, [9] [10] [11] [12] The objective of this noninterventional trial was to prove the efficacy and safety in daily medical practice of a new Vitex preparation in patients with PMS. The approach was to differentiate between the different symptom complexes of PMS. A pronounced psychological aspect is characteristic of this syndrome. 15, 16 This is reflected by the considerable decrease in the number of patients with psychic complaints after a mean treatment period of 3 months, exceeding the decrease in somatic symptoms, which itself was significant. More than 40% of all patients reported a complete cessation of all PMS complaints.
The decrease in anxiety symptoms was remarkably high, supporting the opinion that the psychological aspect of PMS must not be neglected. The occurrence of hyperhydration is the most variable and persistent symptom. After 3 months of treatment, . 40% of patients still suffered from complaints of hyperhydration, but data on the mean number of symptoms and days with PMS complaints per menstrual cycle show that although the complaints did not cease entirely, the severity had diminished during the treatment phase. The qualitative record of mastodynia, the main symptom not only of the hyperhydration complex but of PMS in general, 10 supports this view. Although 30% of the women still complained about mastodynia after Vitex treatment, most of them reported that the complaints were clearly of lower intensity.
In 93% of the documented cases, the number of PMS symptoms decreased, and 95% of the patients experienced an improvement, whereas physicians assessed the therapeutic efficacy in 96% of the cases as at least moderate. This good efficacy is accompanied by equally good drug safety. The global assessment of tolerance-only 1% of patients rated it as bad-is supported by the low rate of suspected adverse drug reactions documented by the investigators for 1% of the women. These adverse events affected mainly the gastrointestinal tract, the skin, and the integumentary system. No data beyond the current knowledge on the safety of Vitex treatment were obtained. 6 Data from this trial support the occasionally described restoration of fertility by Vitex treatment. 6, 18 No woman was pregnant at the start of Vitex therapy, and 19 of the 23 women who conceived while on Vitex treatment belonged to the group of 126 women (8%) who had been to date unsuccessful at becoming pregnant. This observation may be explained by the effect of Vitex on corpus luteum insufficiency.
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CONCLUSIONS
A positive risk/benefit ratio exists for this Vitex preparation (Femicur ® ) in the treatment of PMS. In addition, this investigation examined the efficacy of Vitex in more detail by differentiating between characteristic PMS symptoms and the four DACH complexes. Vitex was proven to be effective with respect to all psychic and somatic symptoms of the heterogeneous and multifaceted PMS.
